Drug intelligence / Profile preview

225Ac-PSMA-313

Development stage: Unknown
Lead developer: C Ray Therapeutics
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

225Ac-PSMA-313 is an investigational radiopharmaceutical designed for targeted alpha therapy in prostate cancer. It consists of a ligand that binds specifically to the prostate-specific membrane antigen (PSMA), which is highly expressed on prostate cancer cells, conjugated with the alpha-emitting radioisotope actinium-225 (225Ac). Upon binding to PSMA-expressing tumor cells, the drug delivers potent alpha radiation directly to malignant tissue, aiming to induce double-stranded DNA breaks and cell death while minimizing damage to surrounding healthy tissues. The primary indication under investigation is metastatic castration-resistant prostate cancer (mCRPC)[4]. The drug is currently being evaluated in clinical trials for safety and efficacy.

Other names: 225Ac-PSMA-313

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 225Ac-PSMA-313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 225Ac-PSMA-313.

Explore the full profile